Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2019

Open Access 01-12-2019 | Neurofibromatosis | Research

Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool

Authors: Marie-Laure Armand, Charles Taieb, Aline Bourgeois, Mireille Bourlier, Mohammed Bennani, Christine Bodemer, Pierre Wolkenstein, along with the French national network on rare skin diseases (FIMARAD)

Published in: Orphanet Journal of Rare Diseases | Issue 1/2019

Login to get access

Abstract

Background

Neurofibromatosis Type 1 (NF1) is a common genetic neurocutaneous disease, with an autosomal dominant inheritance mode. Quality of life has been shown impaired in NF1, due to severe complications, cosmetic features, and uncertainty about the disorder.

Methods

This study sought to develop a self-administered questionnaire in French to assess the burden of NF1 (BoN), then translate and linguistically and cross-culturally validate it into American English, standardized methodology applied, as outlined in the report.

Results

Based on several discussions with NF1 patients, a 17-item conceptual questionnaire was first produced. Of the 91 NF1 adult patients who responded to the conceptual questionnaire, 65 (64.6% females) were accessible. Subsequent confirmatory analyses generated a 15-item questionnaire grouped into four domains, demonstrating internal consistency (Cronbach’s alpha: 091), discriminant validity, and high reliability. The BoN was likewise shown to significantly correlate with other validated questionnaires, such as Dermatology Life Quality Index, Perceived Stress Scale, and SF12 mental score, indicating good external validity.

Conclusions

BoN is a specific tool for assessing the burden that NF1 generates on many practical aspects of the patient daily activities, beyond the notion of quality of life”. Given the increasing relevance that regulatory authorities attribute to patient-reported outcomes, the BoN questionnaire provides such supplementary information while accounting for the burden of NF1 patients in the broadest sense.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cawthon RM, Weiss R, Xu GF, Viskochil D, Culver M, Stevens J, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell. 1990;62:193–201.CrossRefPubMed Cawthon RM, Weiss R, Xu GF, Viskochil D, Culver M, Stevens J, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell. 1990;62:193–201.CrossRefPubMed
2.
go back to reference Xu GF, O'Connell P, Viskochil D, Cawthon R, Robertson M, Culver M, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell. 1990;62:599–608.CrossRefPubMed Xu GF, O'Connell P, Viskochil D, Cawthon R, Robertson M, Culver M, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell. 1990;62:599–608.CrossRefPubMed
3.
go back to reference Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p2. Cell. 1990;63:843–9.CrossRefPubMed Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p2. Cell. 1990;63:843–9.CrossRefPubMed
4.
5.
go back to reference Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet. 2010;152:327–32.CrossRef Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet. 2010;152:327–32.CrossRef
6.
go back to reference Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997;278:51–7.CrossRefPubMed Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997;278:51–7.CrossRefPubMed
7.
go back to reference Griffiths S, Thompson P, Frayling I, Upadhyaya M. Molecular diagnosis of neurofibromatosis type 1: 2 years experience. Familial Cancer. 2006;6:21–34.CrossRef Griffiths S, Thompson P, Frayling I, Upadhyaya M. Molecular diagnosis of neurofibromatosis type 1: 2 years experience. Familial Cancer. 2006;6:21–34.CrossRef
8.
go back to reference Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13:834–43.CrossRefPubMed Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13:834–43.CrossRefPubMed
9.
go back to reference Sorensen SA, Mulvihill JJ, Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med. 1986;314:1010–5.CrossRefPubMed Sorensen SA, Mulvihill JJ, Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med. 1986;314:1010–5.CrossRefPubMed
10.
go back to reference Hernández-Martín A, Duat-Rodríguez A. An update on neurofibromatosis type 1: not just café-au-lait spots and freckling. Part II. Other skin manifestations characteristics of NF1. NF1 and cancer. Actas Dermosifiliogr. 2016;107:465–73.CrossRefPubMed Hernández-Martín A, Duat-Rodríguez A. An update on neurofibromatosis type 1: not just café-au-lait spots and freckling. Part II. Other skin manifestations characteristics of NF1. NF1 and cancer. Actas Dermosifiliogr. 2016;107:465–73.CrossRefPubMed
11.
go back to reference Belzeaux R, Lançon C. Neurofibromatosis type 1: psychiatric disorders and quality of life impairment. Presse Med. 2006;35:277–80.CrossRefPubMed Belzeaux R, Lançon C. Neurofibromatosis type 1: psychiatric disorders and quality of life impairment. Presse Med. 2006;35:277–80.CrossRefPubMed
12.
go back to reference Burris CKH, Stier MA, Salamat S, Thomas S, Lauderdale S, Raven ML, et al. Neurofibromatosis type 1: a neuro-psycho-cutaneous syndrome? Orbit. 2017;20:1–4. Burris CKH, Stier MA, Salamat S, Thomas S, Lauderdale S, Raven ML, et al. Neurofibromatosis type 1: a neuro-psycho-cutaneous syndrome? Orbit. 2017;20:1–4.
13.
go back to reference Pasini A, Lo-Castro A, Di Carlo L, Pitzianti M, Siracusano M, Rosa C, Galasso C. Detecting anxiety symptoms in children and youths with neurofibromatosis type I. Am J Med Genet B Neuropsychiatr Genet. 2012;159:869–73.CrossRef Pasini A, Lo-Castro A, Di Carlo L, Pitzianti M, Siracusano M, Rosa C, Galasso C. Detecting anxiety symptoms in children and youths with neurofibromatosis type I. Am J Med Genet B Neuropsychiatr Genet. 2012;159:869–73.CrossRef
14.
go back to reference Vranceanu AM, Merker VL, Park E, Plotkin SR. Quality of life among adults with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. J Neuro-Oncol. 2013;114:257–62.CrossRef Vranceanu AM, Merker VL, Park E, Plotkin SR. Quality of life among adults with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. J Neuro-Oncol. 2013;114:257–62.CrossRef
15.
go back to reference Michaud CM, McKenna MT, Begg S, Tomijima N, Majmudar M, Bulzacchelli MT, et al. The burden of disease and injury in the United States 1996. Popul Health Metrics. 2006;4:11.CrossRef Michaud CM, McKenna MT, Begg S, Tomijima N, Majmudar M, Bulzacchelli MT, et al. The burden of disease and injury in the United States 1996. Popul Health Metrics. 2006;4:11.CrossRef
16.
go back to reference Chren MM, Weinstock MA. Conceptual issues in measuring the burden of skin diseases. J Investig Dermatol Symp Proc. 2004;9:97–100.CrossRefPubMed Chren MM, Weinstock MA. Conceptual issues in measuring the burden of skin diseases. J Investig Dermatol Symp Proc. 2004;9:97–100.CrossRefPubMed
18.
go back to reference Meyer N, Paul C, Feneron D, Bardoulat I, Thiriet C, Camara C, et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol. 2010;24:1075–82.PubMed Meyer N, Paul C, Feneron D, Bardoulat I, Thiriet C, Camara C, et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol. 2010;24:1075–82.PubMed
19.
go back to reference Boccara O, Méni C, Léauté-Labreze C, Bodemer C, Voisard J, Dufresne H, et al. Haemangioma family burden: creation of a specific questionnaire. Acta Derm Venereol. 2015;95:78–82.CrossRefPubMed Boccara O, Méni C, Léauté-Labreze C, Bodemer C, Voisard J, Dufresne H, et al. Haemangioma family burden: creation of a specific questionnaire. Acta Derm Venereol. 2015;95:78–82.CrossRefPubMed
20.
go back to reference Dufresne H, Hadj-Rabia S, Méni C, Sibaud V, Bodemer C, Taïeb C. Family burden in inherited ichthyosis :creation of a specific questionnaire. Orphanet J Rare Dis. 2013;8:28.CrossRefPubMedPubMedCentral Dufresne H, Hadj-Rabia S, Méni C, Sibaud V, Bodemer C, Taïeb C. Family burden in inherited ichthyosis :creation of a specific questionnaire. Orphanet J Rare Dis. 2013;8:28.CrossRefPubMedPubMedCentral
21.
go back to reference Taïeb A, Boralevi F, Seneschal J, Merhand S, Georgescu V, Taieb C, Ezzedine K. Atopic dermatitis: development and validation of a new assessment tool. Acta Derm Venereol. 2015;95:700–5.CrossRefPubMed Taïeb A, Boralevi F, Seneschal J, Merhand S, Georgescu V, Taieb C, Ezzedine K. Atopic dermatitis: development and validation of a new assessment tool. Acta Derm Venereol. 2015;95:700–5.CrossRefPubMed
22.
go back to reference Salzes C, Abadie S, Seneschal J, Whitton M, Meurant JM, Jouary T, et al. The vitiligo impact patient scale (VIPs): development and validation of a vitiligo burden assessment tool. J Invest Dermatol. 2016;136:52–8.CrossRefPubMed Salzes C, Abadie S, Seneschal J, Whitton M, Meurant JM, Jouary T, et al. The vitiligo impact patient scale (VIPs): development and validation of a vitiligo burden assessment tool. J Invest Dermatol. 2016;136:52–8.CrossRefPubMed
23.
go back to reference Ferner RE, Thomas M, Mercer G, et al. Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the impact of NF1 on quality of life (INF1-QOL) questionnaire. Health Qual Life Outcomes. 2017;15(1):34.CrossRefPubMedPubMedCentral Ferner RE, Thomas M, Mercer G, et al. Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the impact of NF1 on quality of life (INF1-QOL) questionnaire. Health Qual Life Outcomes. 2017;15(1):34.CrossRefPubMedPubMedCentral
24.
go back to reference Seidenberg M, Haltiner A, Taylor MA, Hermann BB, Wyler A. Development and validation of a multiple ability self-report questionnaire. J Clin Exp Neuropsychol. 1994;16:93–104.CrossRefPubMed Seidenberg M, Haltiner A, Taylor MA, Hermann BB, Wyler A. Development and validation of a multiple ability self-report questionnaire. J Clin Exp Neuropsychol. 1994;16:93–104.CrossRefPubMed
25.
go back to reference Cronbach LJ, Warrington WG. Time-limit tests: estimating their reliability and degree of speeding. Psychometrika. 1951;6:167–88.CrossRef Cronbach LJ, Warrington WG. Time-limit tests: estimating their reliability and degree of speeding. Psychometrika. 1951;6:167–88.CrossRef
26.
27.
go back to reference Finlay AY, Khan GK. Dermatology life quality index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–6.CrossRefPubMed Finlay AY, Khan GK. Dermatology life quality index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–6.CrossRefPubMed
28.
go back to reference Lewis V, Finlay AY. 10 years experience of the dermatology life questionnaire. J Investig Dermatol Symp Proc. 2004;9:169–80.CrossRefPubMed Lewis V, Finlay AY. 10 years experience of the dermatology life questionnaire. J Investig Dermatol Symp Proc. 2004;9:169–80.CrossRefPubMed
29.
go back to reference Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24:385–96.CrossRefPubMed Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24:385–96.CrossRefPubMed
30.
go back to reference Cohen S, Williamson G. Perceived stress in a probability sample of the United States. In: Spacapan S, Oskamp S, editors. The social psychology of health: Claremont symposium on applied social psychology. Newbury Park: Sage; 1988. Cohen S, Williamson G. Perceived stress in a probability sample of the United States. In: Spacapan S, Oskamp S, editors. The social psychology of health: Claremont symposium on applied social psychology. Newbury Park: Sage; 1988.
31.
go back to reference Lim LL, Fisher JD. Use of the 12-item short-form (SF-12) health survey in an Australian heart and stroke population. Qual Life Res. 1999;8:1–8.CrossRefPubMed Lim LL, Fisher JD. Use of the 12-item short-form (SF-12) health survey in an Australian heart and stroke population. Qual Life Res. 1999;8:1–8.CrossRefPubMed
32.
go back to reference Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, et al. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation. Value Health. 2005;8:94–104.CrossRefPubMed Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, et al. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation. Value Health. 2005;8:94–104.CrossRefPubMed
33.
go back to reference Samuelsson B, Riccardi VM. Neurofibromatosis in Gothenburg, Sweden, III: psychiatric and social aspects. Neurofibromatosis. 1989;2:84–106.PubMed Samuelsson B, Riccardi VM. Neurofibromatosis in Gothenburg, Sweden, III: psychiatric and social aspects. Neurofibromatosis. 1989;2:84–106.PubMed
34.
go back to reference Mauger D, Zeller J, Revuz J, Wolkenstein P. Psychological impact of neurofibromatosis type 1. Ann Dermatol Venereol. 1999;126:619–20.PubMed Mauger D, Zeller J, Revuz J, Wolkenstein P. Psychological impact of neurofibromatosis type 1. Ann Dermatol Venereol. 1999;126:619–20.PubMed
35.
go back to reference Page PZ, Page GP, Ecosse E, Korf BR, Leplege A, Wolkenstein P. Impact of neurofibromatosis 1 on quality of life: a cross-sectional study of 176 American cases. Am J Med Genet A. 2006;140:1893–8.CrossRefPubMed Page PZ, Page GP, Ecosse E, Korf BR, Leplege A, Wolkenstein P. Impact of neurofibromatosis 1 on quality of life: a cross-sectional study of 176 American cases. Am J Med Genet A. 2006;140:1893–8.CrossRefPubMed
36.
go back to reference Garcia-Penas JJ. Learning disorders in neurofibromatosis type 1. Rev Neurol. 2017;64:59–63. Garcia-Penas JJ. Learning disorders in neurofibromatosis type 1. Rev Neurol. 2017;64:59–63.
37.
go back to reference Kodra Y, Giustini S, Divona L, Porciello R, Calvieri S, Wolkenstein P, et al. Health-related quality of life in patients with neurofibromatosis type 1. A survey of 129 Italian patients. Dermatology. 2009;218:215–20.CrossRefPubMed Kodra Y, Giustini S, Divona L, Porciello R, Calvieri S, Wolkenstein P, et al. Health-related quality of life in patients with neurofibromatosis type 1. A survey of 129 Italian patients. Dermatology. 2009;218:215–20.CrossRefPubMed
38.
go back to reference Leidy NK, Revicki DA, Genesté B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health. 1999;2:113–27.CrossRefPubMed Leidy NK, Revicki DA, Genesté B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health. 1999;2:113–27.CrossRefPubMed
39.
go back to reference Wagner T. Using questionnaires in clinical research – a guide through the data jungle. J Clin Study. 2014;6:52–4. Wagner T. Using questionnaires in clinical research – a guide through the data jungle. J Clin Study. 2014;6:52–4.
Metadata
Title
Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool
Authors
Marie-Laure Armand
Charles Taieb
Aline Bourgeois
Mireille Bourlier
Mohammed Bennani
Christine Bodemer
Pierre Wolkenstein
along with the French national network on rare skin diseases (FIMARAD)
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2019
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-019-1067-8

Other articles of this Issue 1/2019

Orphanet Journal of Rare Diseases 1/2019 Go to the issue